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ABSTRACT OF THE DISSERTATION 
PREDICTORS OF ADHERENCE, WITHDRAWAL SYMPTOMS AND CHANGES IN BODY 
MASS INDEX: FINDING FROM THE FIRST RANDOMIZED SMOKING CESSATION 
TRIAL IN A LOW-INCOME COUNTRY SETTING  
by 
Ziyad Ben Taleb 
Florida International University, 2016 
Miami, Florida 
Professor Wasim Maziak, Major Professor 
The most commonly attributed causes of failure of smoking cessation are non-adherence 
to treatment, experiencing severe nicotine withdrawal symptoms and post-cessation weight gain.  
However, there is a lack of information regarding these factors among smokers who attempt to quit 
in low-income country settings. The main objective of this study was to identify predictors of: 1) 
adherence to cessation treatment; 2) severity of withdrawal symptoms: and 3) post-cessation 
changes in body mass index among 269 smokers who attempted to quit in a randomized smoking 
cessation trial in a low-income country setting (Aleppo, Syria). All participants received behavioral 
counseling and were randomized to receive either 6 weeks of nicotine or placebo patch and were 
followed for one year.   
Findings from logistic regression showed that lower adherence to cessation treatment was 
associated with higher daily smoking, greater withdrawal symptoms, waterpipe use, being on 
placebo patch and the perception of receiving placebo patch. Generalized estimating equation 
(GEE) analyses indicated that throughout the study, lower total withdrawal score was associated 
with greater education, older age of smoking initiation, higher confidence in ability to quit, higher 
adherence to patch, lower nicotine dependence, lower reported depression, waterpipe use and  the 
perception of receiving nicotine patches rather than placebo. Further, smoking abstainers gained 
vii 
 
1.8 BMI units (approximately 4.8kg) greater than non-abstainers over one year post quitting. In 
addition, greater BMI was associated with being female, smoking to control weight and having 
previously failed to quit due to weight gain.  
In conclusion, nicotine dependence, waterpipe use and expectancies regarding cessation 
treatment are important factors that influence adherence to cessation treatment and severity of 
nicotine withdrawal symptoms. Moreover, targeted interventions that take into consideration the 
prevailing local and cultural influences on diet and levels of physical activity are recommended 
especially for females and smokers with weight concerns prior to quitting. Collectively, these 
findings will help in conducting future tailored effective cessation programs in Syria and other low-
income countries with similar levels of developments and tobacco use patterns. 
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INTRODUCTION 
 
Smoking tobacco kills approximately a third to half of its users, with an estimated 5 million 
annual global deaths, and if current trends continues, the death toll is expected to reach one billion 
by the end of this century (Shafey O, 2009; WHO, 2008; Adcock IM, 2011; Koczulla AR, 2010).  
On average, smokers die 10 to 15 years earlier than non-smokers (USDHHS, 2004).  
Low-income countries are currently struggling with an epidemic of tobacco dependence and its 
complications. By the year 2030, it is predicted that more than 80% of tobacco deaths will be in 
developing countries (WHO, 2008). Most of low-income countries are still in the primary stages 
of the tobacco epidemic; therefore, in the future, this region of the world will most likely continue 
to experience increased smoking prevalence and growing number of tobacco caused diseases and 
deaths (Maziak et al, 2013; Ward et al, 2006).  
Tobacco control, and in particular cessation programs, should be a priority for policy 
makers in low-income countries to achieve a considerable impact in the near future on the morbidity 
and mortality caused by smoking. However, in order for cessation strategies to be implemented 
comprehensively and according to best practices within tobacco control efforts, there is a need to 
overcome many regional challenges and cultural barriers. There is paucity of cessation programs 
in most low-income countries, and the few services that exist are modeled from western programs, 
which have different healthcare infrastructure settings and unique cultural characteristics (Maziak 
et al, 2004). However, despite the WHO’s recommendation that tobacco dependence treatment 
should be a top public health priority (WHO, 2000), very little work has been done to promote and 
implement smoking cessation in low-income countries. 
Smoking cessation is a continuous process that may involve a series of quit attempts 
before long term abstinence is accomplished. Despite that most smokers express a desire to quit, 
only around one third of them make attempts to quit and few are successful (Rigotti, 2002; 
USDHHS, 1990). Furthermore, approximately 80% of quitters relapse before reaching 6 months 
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of abstinence (USDHHS, 1990).  Many factors are associated with failure to quit smoking. Some 
of the most cited factors are experiencing nicotine withdrawal symptoms, non-adherence to 
cessation treatment and gaining weight post-cessation.  
The relationship between adherence to treatment and successful quit attempts is well 
recognized (Raupach et al, 2014).  Therefore, a great deal of attention has been directed toward 
maintaining patient adherence to treatment (e.g., attendance at counseling sessions, taking 
medication as instructed) in smoking cessation interventions (Shiffman et al., 2008; Alterman, 
1999). As such, factors contributing to better adherence to treatment have been investigated in the 
past to guide the development of cessation interventions and to improve cessation rates in high-
income countries (Alterman et al., 1999; Berg et al., 2013; Cooper et al., 2004; Patterson et al., 
2003).  Nevertheless, no studies have looked at patterns and correlates of adherence to cessation 
treatment in a low-income country setting.  
In addition, experiencing nicotine withdrawal symptoms is one of the biggest challenges 
that faces smokers while quitting. When smokers are deprived of nicotine, they develop withdrawal 
symptoms and pronounced cognitive and attentional deficiencies that are relieved when consuming 
nicotine (Evans and Drobes, 2009). Prior research highlighted some of the important factors 
influencing nicotine withdrawal symptoms. These include number of cigarettes smoked per day, 
motivation to smoke, and depression (Morrell et al 2008; West and Russell 1985). Despite the 
extensive literature on evaluating nicotine withdrawal symptoms in populations from high-income 
countries (Bidwell et al. 2013; Gritz et al. 1991; Hendricks and Leventhal 2013; Hendricks et al. 
2014; Neiro et al. 2014; Piasecki et al. 2003; West et al.2008), such information in low-income 
countries lags behind.   
Finally, post-cessation weight gain is commonly cited as a major cause of failure to quit 
smoking (Jeffery et al., 2000; Perkins, 1993).   It is a well-established, that quitters gain weight 
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after stopping smoking (Flegal et al., 1995). In general, quitters gain an average of 4 to 5 kg after 
one year (Aubin et al., 2012). One of the most important consequences of weight gain post smoking 
cessation is relapsing back to smoking (Klesges et al., 1997). Evidence from high-income countries 
has documented several factors associated with post-cessation weight gain such as higher nicotine 
dependence and lower socioeconomic status (Wane et al., 2010; Williamson et al 1991; Swan and 
Carmelli, 1995).  However, prevalence and predictors of post-cessation weight gain may be 
different in low income compared to high income countries, since many risk factors differ.  For 
example, people living in low-income countries may be less concerned about weight gain and have 
different rates of obesity than those living in high-income countries probably due to differences in 
socioeconomic status, and cultural and life style factors such as level of physical activity and diet 
choices (Badran and Laher, 2011; Fouad et al., 2006).  
In Summary, lack of information regarding factors that influence adherence to cessation 
treatment, severity of nicotine withdrawal symptoms and weight gain among smokers who attempt 
to quit in low-income country settings warrant further research. The aim of this dissertation is to 
identify predictors of adherence to cessation treatment, nicotine withdrawal symptoms and changes 
in body mass index (BMI) among smokers who participated in a randomized cessation trial in a 
primary health care setting in Aleppo, Syria.  
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MANUSCRIPT 1 
© Copyright 2016 
Ben Taleb, Z, Ward, K. D., Asfar, T., Bahelah, R., & Maziak, W. (2015). Predictors of adherence 
to pharmacological and behavioral treatment in a cessation trial among smokers in Aleppo, 
Syria. Drug and Alcohol Dependence, 153, 167-172 
Abstract 
Background: The development of evidence-based smoking cessation programs is in its infancy in 
developing countries, which continue to bear the main brunt of the tobacco epidemic. Adherence 
to treatment recommendations is an important determinant of the success of smoking cessation 
programs, but little is known about factors influencing adherence to either pharmacological or 
behavioral treatment in developing countries settings. Aim: To examine the predictors of adherence 
to cessation treatment in a low-income developing country. Methods: Predictors of adherence to 
pharmacological and behavioral treatment were identified by analyzing data from a multi-site, two-
group, parallel-arm, double-blind, randomized, placebo-controlled smoking cessation trial in 
primary care clinics in Aleppo, Syria. Participants received 3 in-person behavioral counseling 
sessions plus 5 brief follow-up phone counseling sessions, and were randomized to either 6 weeks 
of nicotine or placebo patch. Results: Of the 269 participants, 68% adhered to pharmacological 
treatment, while 70% adhered to behavioral counseling. In logistic regression modeling, lower 
adherence to pharmacological and behavioral treatment was associated with higher daily smoking 
at baseline, greater withdrawal symptoms, and perception of receiving placebo instead of active 
nicotine patch. Women showed lower adherence than men to behavioral treatment, while being 
assigned to placebo condition and baseline waterpipe use were associated with lower adherence to 
pharmacological treatment. Conclusion: Adherence to cessation treatment for cigarette smokers in 
low-income countries such as Syria may benefit from integrated cessation components that provide 
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intensive treatment for subjects with higher nicotine dependence, and address concurrent waterpipe 
use at all stages. 
KEYWORDS: adherence; cessation; cigarettes; developing countries; smoking 
Introduction 
Tobacco smoking remains the leading cause of preventable deaths world-wide. Currently, 
tobacco is responsible for an estimated 6 million deaths every year (Erikson et al, 2013). This 
annual death toll is expected to increase to 10 million within the next 20–30 years, with 80% of 
these deaths occurring in developing countries (WHO, 2013a).  These trends call for comprehensive 
approaches for tobacco control, especially in low-income countries, which continue to bear most 
of the brunt of the tobacco epidemic (World Bank, 2010). 
Promoting smoking cessation, is a cornerstone in the fight to reduce tobacco related 
morbidity and mortality (WHO, 2013a).  This is why, one of the main articles (14) of the 
Framework Convention on Tobacco Control (FCTC) requires governments to take effective 
measures to promote cessation of tobacco use and adequate treatment for tobacco dependence 
(WHO, 2010). At least in developed countries, the application of a mixture of behavioral and 
pharmacological cessation interventions has been shown to help a proportion of smokers to quit 
smoking (Fiore et al., 2008). Unfortunately, in developing countries, where most of the world 
smokers reside (Jha et al., 2006), infrastructure for smoking cessation is lacking and little work is 
being done to develop effective cessation interventions that take into account local smoking 
patterns, health care resources and culture. (Maziak et al., 2004). For example, in Syria, a Middle 
Eastern country with high prevalence of cigarettes and waterpipe smoking (WHO, 2013b;Ward et 
al., 2006) there are no clinical practice standards, specialty cessation clinics or pharmacological 
agents available to assist smokers to quit (Asfar et al., 2008, 2011; Maziak et al., 2004; Ward et al, 
2013). 
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To date there is only one randomized clinical trial of a behavioral/pharmacological 
smoking cessation intervention that was conducted in a developing country setting (Ward et al., 
2013).  Results from this trial showed that combined pharmacological and behavioral treatment 
induced cessation in 12% of participants at one year post-treatment. This study along with a bulk 
of evidence from developed countries highlighted the importance of adherence to treatment (e.g., 
attendance at counseling sessions, taking medication as instructed) in predicting successful 
cessation outcomes (Shiffman et al., 2008; Alterman, 1999). As such, factors contributing to better 
adherence to cessation treatment have received substantial attention in order to guide the 
development of approaches that improve adherence to cessation interventions (Alterman et al., 
1999; Berg et al., 2013; Cooper et al., 2004; Patterson et al., 2003).  However, little if any evidence 
currently exists to assist in fostering adherence to cessation treatments in developing countries. The 
current study aims to address this knowledge gap by identifying potential predictors of adherence 
to pharmacological and behavioral treatment in a developing country’s health care setting (Syria).  
Methods 
Study design 
  This study utilized data from a multi-site two-group, parallel-arm, double-blind, 
randomized, placebo-controlled trial conducted in primary care clinics in Aleppo, Syria from 2007 
to 2008. Full details of the trial and methods are published elsewhere (Ward et al., 2013).  Eligible 
and interested smokers were randomized to receive either behavioral cessation counseling + active 
transdermal nicotine patches (TN) or behavioral cessation counseling + placebo TN. A total of 269 
smokers were recruited, 18-65 years old, who had smoked > 5 cigarettes/day for at least one year. 
Participants were patients who resided within the catchment area of one of the four primary health 
care clinics included in the study.  Each clinic had a primary care physician who served as a 
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cessation coordinator, liaised between other physicians and clinic-staff to ensure adherence to the 
study protocol, and delivered the intervention to participants. 
Pharmacologic Intervention 
Patients in the active treatment group received a six-week supply of Nicotinell™ patches, 
24-hour dose, using a step-down algorithm. Patients in the placebo group received the same step-
down algorithm. Placebo patches were provided by a local manufacturer.  
Behavioral counselling 
All patients received behavioral cessation counseling using approaches shown to be 
effective in developed countries (Abrams and Niaura, 2003; Fiore et al., 2008) and adapted for the 
local culture based on previous research (Asfar et al., 2008). Three individual, in-person sessions 
(approximately 30 minutes each) and 5 brief (approximately 10-minute) phone calls, were delivered 
by the cessation coordinator. Participants provided baseline demographic data, smoking related 
information (e.g., smoking history, level of dependence, previous quit attempts, readiness to quit 
smoking), and completed additional questionnaires to assess quitting self-efficacy, stage of change, 
withdrawal symptoms, perceived social support, and depression/mood.  Participants then were 
assigned to one of two treatment conditions [Arm A (n=134): behavioral counseling + active TN 
vs. Arm B (n=135): behavioral counseling + placebo TN] using random permuted blocks, stratified 
by clinic and gender. 
Measures 
Baseline predictors 
Socio-demographic variables included age, gender, marital status, number of people in the 
house, years of education and religion. Smoking-related variables included number of years as a 
cigarette smoker; current amount smoked (cigarettes/day); previous successful quit attempts 
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defined as quitting smoking for at least 24 hours in the past six months; the Readiness To Quit 
Ladder (Biener and Abrams, 1991); a single item, Likert-type scale assessing confidence in one’s 
ability to quit; the three subscales of the Smoking Self-Efficacy/Temptations Questionnaire (Long 
Form)—Positive Affect/Social Situations, Negative Affect Situations, and Habitual/Craving 
Situations (Velicer et al. ,1990); the Fagerström Test for Nicotine Dependence (FTND) (Heatherton 
et al. ,1991); waterpipe use status and tobacco withdrawal symptomatology using the Minnesota 
Nicotine Withdrawal Scale (MNWS) (Hughes and Hatsukami, 1986). We calculated the mean of 
eight scale items to obtain a total withdrawal score. Other variables included: perceived social 
support (Zimet et al., 1988; Zimet et al., 1990), and depressive symptomatology using the Center 
for Epidemiologic Studies Depression Scale (CES-D) (Radloff, 1977; Thomas et al., 2001). To 
assess blindness during treatment, patients indicated whether they believed they had received 
nicotine or placebo patch. 
Adherence to patch 
Participants were queried weekly for the duration of the treatment (six weeks) on whether 
they had followed treatment instructions to use one patch every day over the past week. Based on 
the literature (Kopjar et al., 2003; Nachega et al., 2006; Ruddy and  Partridge, 2009, Berg et al., 
2013), we defined being adherent to patch use as responding “yes” to this question during at least 
5 of the 6 weeks (>80%). Accordingly, adherence to patch was set up as a dichotomous variable 
(non-adherent=0, adherent=1). 
Adherence to behavioral counselling 
Following previous work (Asfar et al., 2008; Klesges et al., 1988; Mizes et al., 1998; 
Patterson et al., 2003), adherence to behavioral counselling was set as a dichotomous variable (non-
adherent=0, adherent=1) indicating whether the subjects completed all vs. some sessions.  
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Specifically, the variable distinguished participants who completed all three in-person sessions + 
five phone calls from those who missed at least one session or a phone call.  
Statistical Analysis  
Baseline characteristics (socio-demographic, smoking and psychosocial characteristics) 
were compared according to adherence to pharmacological and behavioral treatment for all subjects 
using the chi-square test for categorized variables and t-tests or Mann–Whitney U tests where 
appropriate for continuous variables. Bivariate correlations for all predictor variables revealed no 
multicollinearity. This was also inspected by checking for extraordinary estimated coefficients and 
standard errors, which would have suggested the existence of collinearity. The outcomes of interest 
were adherence to patch use and adherence to behavioral counseling. Separate logistic regression 
models were developed for each outcome variable. All predictors (socio-demographic, smoking-
related, and psychosocial variables) significant at the < 0.20 level in bivariate analyses were entered 
into the models using backward stepwise entry, with only those variables contributing at the < 0.05 
level being allowed to remain in the model. The Wald statistic was used to assess the contribution 
of each predictor to the overall model.  Adjusted odd ratios and 95 % Confidence intervals were 
calculated and reported. All analyses controlled for age and sex. Data were analyzed using SPSS 
version 21 (SPSS Inc., Chicago, IL, USA). 
Results 
Characteristics of the sample 
Males comprised 78 % of the sample. The mean age was 39.9 years (SD=11.4), with a 
mean of 10.2 years of education (SD=4.0). The mean number of cigarettes smoked per day was 
27.7 (SD= 12.7), while the mean age for the onset of daily smoking was 18.6 years (SD=5.3) and 
the mean Fagerström nicotine dependence score was 5.7 (SD=2.2). The two treatment groups 
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(nicotine vs. placebo) did not differ significantly on any of these variables at baseline. Out of the 
269 study participants, 183 (68%) were adherent to patch use and 187 (70%) were adherent to 
behavioral counselling sessions. To assess blindness during treatment, patients indicated whether 
they believed they had received nicotine or placebo patch, in which 62% of participants on nicotine 
patch guessed their assignment correctly as compared to only 40% of participants on placebo patch 
(P <0.001). 
Bivariate associations 
Table1 summarizes the bivariate analysis for baseline characteristics by adherence to patch 
and behavioral counseling. 
Adherence to patch use  
Lower adherence was associated with greater number of cigarettes smoked per day at 
baseline (P = 0.001), higher FTND score (P=.041), waterpipe smoking (P=.005), self-perception of 
being allocated to placebo group (P= <.001), greater total withdrawal symptoms (P=.036), being 
on placebo treatment (P = 0.002), and lower readiness to quit score (P=.033).  
Adherence to behavioral counseling 
Lower adherence to behavioral treatment was associated with greater number of cigarettes 
smoked per day at baseline (P=.002), self-perception of being allocated to placebo group (P= 
<.001), greater total withdrawal symptoms (P=.022) lower readiness to quite score (P=.027), and 
younger age (P=.024).  
Regression modelling 
For the adjusted model predicting adherence to pharmacologic treatment (Table.2), 
participants who received nicotine patch (OR=2.5; 95% CI = 1.3-4.7), perceived themselves as 
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being on nicotine patch (OR=4.3; 95% CI = 2.2-9.3), and who did not use waterpipe (OR=4.2; 95% 
CI =1.6-11.1), were more likely to adhere to patch usage. Participants who smoked a greater 
number of cigarettes per day at baseline (OR=0.97; 95% CI =0.94-0.99) and had higher withdrawal 
symptoms (OR=0.97; 95% CI= 0.95-0.98) were less likely to adhere to patch usage.  
The adjusted model predicting adherence to behavioral counseling (Table.2) shows that 
male participants (OR=2.4; 95% CI=1.2-4.9) and those who perceived themselves as being on 
nicotine patch (OR=4.6; 95% CI =2.4-8.8) were more likely to adhere to counseling. On the other 
hand, participant who smoked a greater number of cigarettes per day at baseline (OR=0.97; 95% 
CI =0.94-0.98) and who had higher withdrawal score (OR=0.98; 95% CI =0.96-0.99) were less 
likely to adhere to counseling. 
For both study outcomes, we examined several interaction terms, including treatment group 
with baseline withdrawal score, number of cigarettes smoked per day, and perception of treatment 
allocation (i.e., belief that one had received nicotine and not placebo).  We also examined the 
interaction between gender and baseline withdrawal score. All interaction terms yielded non-
significant results (all p-values were > 0.27). 
Discussion 
This is the first study to examine predictors of adherence to smoking cessation treatment 
in a developing country’s health care context. Our findings indicate that lower adherence to 
pharmacological and behavioral treatments was associated with heavier smoking rate at baseline, 
greater withdrawal symptomatology, and participants’ belief they were receiving placebo instead 
of active nicotine patch.  Women showed lower adherence than men to behavioral treatment, while 
being assigned to the placebo condition and baseline waterpipe use were associated with lower 
adherence to pharmacologic treatment. Our findings suggest that adherence to cessation treatment 
for cigarette smokers in low-income countries such as Syria may benefit from integrated cessation 
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components that provide intensive treatment for subjects with higher nicotine dependence, and 
address concurrent waterpipe use at all stages. Such novel insights on factors that influence 
adherence to cessation treatment in a developing country’s setting, can help improve cessation 
treatments for smokers living in countries at similar level of development.  
Adherence rates to pharmacological and behavioral treatment achieved in this study 
appears comparable to studies that have been done in developed countries. For example, the 
adherence rate to pharmacological treatment in our study (68%) was in agreement with a previous 
study that examined adherence to medication among adult smokers in two smoking cessation trials 
in the US (Hays et al., 2010). Moreover, adherence rate to behavioral counseling sessions of 70% 
achieved in our study also appears comparable with rates achieved in a cessation trial that evaluated 
adherence to seven sessions of behavioral counseling among adult smokers in the US. (Patterson 
et al., 2003). This shows that high adherence rates can be achieved in developing country settings 
when applying standardized procedures and protocols to follow-up with study’s participants. 
Overall, our study indicates the importance of nicotine dependence as a barrier to 
adherence to pharmacological and behavioral cessation treatments.  Greater tobacco use at baseline 
and more severe tobacco withdrawal symptomatology both indicate greater dependence, and were 
associated with lower adherence in our study.  A higher FTND score also was associated with lower 
adherence in bivariate level (P= .041), although such association was outside the significant level 
in the multivariable models.  While nicotine dependence appears to make adherence difficult, it is 
encouraging that in the current study, the assignment to active nicotine, compared to placebo, was 
associated with a more than two folds greater odds of being adherent to pharmacologic treatment.  
This indicates that nicotine replacement therapy can enhance adherence to treatment in highly 
dependent smokers. 
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One of the unique findings of this study that is likely to be relevant to most countries in the 
Middle East, is the association between lower adherence to pharmacological treatment and 
concurrent waterpipe use. Waterpipe is a common form of tobacco use in the Middle East that 
delivers substantial amounts of nicotine and is associated with nicotine dependence (Aboaziza and 
Eissenberg; Maziak, 2014).  Furthermore, studies that looked into concurrent use of tobacco 
products has shown that dual smokers have the highest prevalence of nicotine dependence in 
contrast to exclusive users (Post et al., 2010; Timberlake, 2008; Tomar et al. 2010). While such 
evidence is indicative of a potential role of nicotine dependence in mediating the association 
between waterpipe smoking and lower adherence, this cannot be asserted based on this finding 
alone. This association however, suggests that cessation efforts in societies, where cigarettes are 
not the only main tobacco use method, should devote special attention to cultural-specific smoking 
behaviors (Maziak et al, 2004, Asfar et al, 2008).  Previous studies from the same population, show 
that cigarette smokers can revert to waterpipe smoking during quit attempts, which can facilitate 
relapse (Hammal et al, 2008; Asfar et al, 2008). As a result, asking about waterpipe smoking and 
emphasizing cessation of all tobacco use can be instrumental to cessation success.  
Interestingly, our data show that women were less adherent to behavioral counselling than 
men. This might be attributed to social barriers and gender roles (Maziak, 2006) that might prevent 
women from freeing themselves from their home duties in order to commit to behavioral 
counselling. Factors such as transportation, child care and other household responsibilities may 
have played a role in lowering women’s adherence to behavioral counselling.  On the other hand, 
adherence to pharmacologic treatment did not differ by gender, which understandably does not 
require attendance and can be done at home.  
Beliefs and expectations about nicotine patch’s effectiveness has been shown to affect 
adherence beyond whether an active nicotine or a placebo patch is received (Darredeau and Barrett, 
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2010). In our study, adherence to pharmacologic and behavioral treatment was greater among those 
who believed that they had received nicotine compared with those who believed they had received 
placebo, regardless of the actual patch assignment. So believing that one may have received a 
nicotine patch even if it was in fact a placebo may have increased compliance or encouraged 
adherence to cessation treatment in general. This suggests that, psychological factors may play an 
important role in participants’ subjective responses to treatment assignment, the effects of which 
cannot be solely attributed to the direct pharmacological effects of nicotine. 
Our study comes with limitations. First, a relatively small sample size may not have 
allowed us to detect differences that were clinically meaningful but not statistically significant. 
Thus, we discussed marginally significant findings that might warrant future investigation. 
Secondly, adherence to patch use was based on self-report. Nevertheless, self-report of adherence 
to treatment has been widely used in the literature for both smoking cessation treatment and other 
medications in general (Alterman, et al., 1999; Cooper et al., 2004; Hollands et al., 2013; Okuyemi 
et al., 2010; Stein et al., 2006).  
Conclusions 
This study provides the first evidence about factors influencing adherence to cessation 
treatments in a low income country setting in the Middle East. It suggests that adherence to 
cessation treatment for cigarette smokers in low-income countries such as Syria may benefit from 
integrated cessation components that provide intensive treatment for subjects with higher nicotine 
dependence, and address concurrent waterpipe use at all stages. 
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Tables and figures 
  
Table 1. Baseline characteristics by adherence to pharmacological and behavioral counseling in a cessation trial among smokers in 
Aleppo, Syria 
*For continuous predictors, a two-sample t-test or Mann–Whitney U test when appropriate evaluated differences in means. For dichotomous predictors, a 
chi-square test evaluated differences in proportions. aRange of possible values for readiness to quit is 0–10. bRange of possible values for the Fagerstrom 
Test of Nicotine Dependence is 0–10. CRange of possible values for confidence in ability to quit is 0–10. dRange of possible values for the social support 
score is 0–60. eRange of possible values for CES-D score is 0–60 
 80% Adherence to pharmacological 
treatment 
 Adherence to behavioral counseling    
 Adherent 
 (n =183 ) 
mean (SD) or 
% 
Non Adherent 
(n =86) 
mean (SD) or % 
p-
value* 
Adherent  
 (n =187) 
mean (SD) or 
% 
Non Adherent 
(n =82) 
mean (SD) or % 
p-value* 
Demographics  
age  40.8(11.1) 38.2(11.7) 0.084 41.0(11.2) 37.6(11.4) 0.024 
Gender (male %) 77.6 80.2 0.751 80.4 73.2 0.185 
Education (years completed) 10.3(4) 10(4) 0.648 10.3(3.8) 10.2(4.6) 0.938 
Number of people in the house  5.4(2.9) 5(2.2) 0.333 5.3(2.8) 5.4(2.6) 0.830 
Marital status (Married %) 80.9 75.6 0.452 82.6 72 0.245 
Religion (Muslim %) 72.7 79.1 0.381 73.9 76.8 0.596 
Tobacco use  
Treatment group (Nicotine %) 56.3 23.1 0.002 53.8 41.5 0.063 
Amount smoked (cigarettes/day) 26(11.7) 31.4(14.1) 0.001 26(11.4) 31.3(14.3) 0.002 
Age when smoked first cigarette 19(5.3) 17.7(5.2) 0.049 18.8(5.3) 18.3(5.2) 0.526 
Readiness to quit scorea 7.9(0.9) 7.6(1.1) 0.033 7.9(0.9) 7.6(0.9) 0.027 
Fagerstrom Test of Nicotine Dependenceb 5.5(2.2) 6.1(2.2) 0.041 5.5(2.2) 6.1(2) 0.060 
Confidence in ability to quitC  6.9 (2.4) 6.9 (2.5) 0.950 6.9(2.2) 6.8(2.6) 0.698 
Carbon monoxide (p.p.m.) 27.4(17.1) 27.8(13.9) 0.822 28(17.1) 26.2(13) 0.404 
Tobacco withdrawal symptoms score 27.3 32.4 0.036 27.2 32.9 0.022 
Water pipe use (%) 7.1 18.6 0.005 9.2 14.6 0.192 
Perception of treatment (placebo %) 30.1 62.3 <0.001 30.4 61.8 <0.001 
Psychosocial   
Social supportd 20.7(11.8) 18.9(11.4) 0.240 20.1(11.7) 19.6(11.5) 0.950 
Depressions (CES-D) scoree 17.6(10.5) 18.8(9.1) 0.358 17.5(10.1) 19.4(10.2) 0.145 
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Table 2. Predictors of adherence to pharmacologic treatment and behavioral counselling in a 
cessation trial among smokers in Aleppo, Syria determined by logistic regression 
Note. CI = confidence interval; OR = odds ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
Adherence to pharmacologic treatment OR CI (95%) P-value 
Treatment group  
Nicotine 
Placebo 
 
2.52 
Ref 
 
1.37–4.78 
 
0.003 
 Water-pipe use 
Non-smoker 
Smoker 
 
4.25 
Ref 
 
1.61–11.1 
 
0.004 
Total withdrawal symptoms score 0.97 0.95–0.98 0.003 
Cigarettes per day 0.97 0.94–0.99 0.014 
Perception of treatment allocation 
Nicotine  
Placebo  
 
4.31 
Ref 
 
2.29–9.31 
 
<0.001 
Adherence to behavioral counselling  OR CI (95%) P-value 
Gender  
Male 
Female 
 
2.41 
Ref 
 
1.21–4.94 
 
0.017 
Total withdrawal symptoms score  0.98 0.96–0.99 0.015 
Cigarettes per day 0.97 0.94–0.98 0.021 
Perception of treatment allocation 
Nicotine  
Placebo  
 
4.61 
Ref 
 
2.41–8.84 
 
<0.001 
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© Copyright 2016 
Ben Taleb, Z., Ward, K.D, Asfar, T., Jaber, R., Auf, R., Maziak, W. (2016). Predictors of nicotine 
withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-
income country setting. International Journal of Public Health.1-8. [Epub ahead of print] 
Abstract 
Background: Inability to cope with withdrawal symptoms when attempting to quit is a major cause 
for failure of cessation. However, little is known about factors influencing nicotine withdrawal 
symptoms in low-income countries.  Aim: To identify predictors of nicotine withdrawal symptoms 
among smokers who participated in a randomized cessation trial in a low-income country. 
Methods: We analyzed data from 269 smokers who participated in a randomized, placebo-
controlled smoking cessation trial conducted in primary healthcare in Aleppo, Syria. All 
participants received behavioral counseling and were randomized to receive either 6 weeks of 
nicotine or placebo patch and were followed for one year.  Results: Throughout the study, lower 
total withdrawal score was associated with greater education (p=0.044), older age of smoking 
initiation (p=0.017), lower nicotine dependence (p=0.024), higher confidence in ability to quit 
(p=0.020), lower reported depression (p<0.001), higher adherence to patch (p=0.026), belief of 
receiving nicotine patches rather than placebo (p=0.011), and waterpipe use (p=0.047). 
Conclusion: Lower nicotine dependence, greater educational attainment, waterpipe use and higher 
confidence in ability to quit predict lower withdrawal severity among participants in a smoking 
cessation intervention in a low-income country setting.  Further, expectancies about the effects of 
pharmacotherapy appear to mediate the experience of nicotine withdrawal. 
KEYWORDS: nicotine, withdrawal, cessation, smoking, low-income countries 
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Introduction 
The need for tobacco cessation interventions in low-income developing countries is 
evident, particularly in countries where tobacco consumption is high and represents a major health 
problem (Ward et al., 2006; World Health Organization, 2011). The spread of heavy smoking 
combined with lack of tested cessation programs makes quitting more challenging for smokers in 
those countries (Maziak et al., 2014). Quitting smoking is known to be difficult, even when aided 
with pharmacological and behavioral therapies (Ray et al., 2009). In fact, especially among chronic 
users, smoking cessation results in unpleasant physiological and psychological symptoms 
collectively known as Nicotine Withdrawal Syndrome. This syndrome is a central constituent of 
tobacco dependence (Hughes et al., 1990). It includes a combination of subjective, cognitive, and 
physiological symptoms that manifest when a smoker tries to quit. These symptoms hinder efforts 
to stop and maintain long-term abstinence from smoking (Shiffman et al., 2004); therefore, the 
inability to cope with withdrawal symptoms when quitting seems to account for a large number of 
failed cessation attempts (West et al., 1989). 
Although accomplishing complete abstinence from smoking is the ultimate goal of 
cessation efforts, nicotine withdrawal symptoms are also of a great interest for two reasons. First, 
withdrawal symptoms have a substantial role in inducing smoking relapse that compromises 
cessation outcomes (Shiffman et al., 2004). In fact, several studies show that the pattern, duration, 
and severity of withdrawal symptoms experienced during cessation attempts are important 
predictors of abstinence among smokers (Allen et al., 2008; Hughes, 2007; Piasecki et al., 2003). 
Second, withdrawal symptoms are considered clinically significant as they cause discomfort and 
distress among smokers who are trying to quit. Therefore, closer examination of the individual 
characteristics that could influence the intensity of nicotine withdrawal symptoms is necessary to 
improve our understanding and management of these symptoms (Shiffman et al., 2004). 
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Prior research highlighted some of the important factors influencing nicotine withdrawal 
symptoms. These include smokers’ baseline serum cotinine levels (measure of nicotine levels), 
number of cigarettes smoked per day, motivation to smoke, and depression (Morrell et al., 2008; 
West and Russell, 1985). Despite the extensive literature on evaluating nicotine withdrawal 
symptoms in populations from high-income countries (Bidwell et al., 2013; Gritz et al., 1991; 
Hendricks and Leventhal, 2013; Hendricks et al., 2014; Morrell et al., 2008; Neiro et al., 2014; 
Piasecki et al., 2003; West and Russell, 1985; West et al., 2008), such information in low-income 
countries lags behind.  Findings from the first cessation trial that was conducted in a low-income 
country setting (Aleppo, Syria), show that having fewer nicotine withdrawal symptoms during 
smoking cessation treatment was associated with a greater likelihood of smoking abstinence (Ward 
et al., 2013). Therefore, there is a great need for further examination of the nature of nicotine 
withdrawal symptoms, and individual factors (e.g., demographic, smoking related and 
psychosocial) that may influence the severity of these symptoms in low-income countries such as 
Syria, which as many other Middle Eastern countries has a different smoking profile in comparison 
to western developed high-income countries (Maziak et al., 2004). 
This study aims to address this knowledge gap by investigating predictors of nicotine 
withdrawal symptoms among smokers who participated in a randomized cessation trial in a low-
income country (Syria).  Our findings will provide insights about factors that influence nicotine 
withdrawal symptomology among smokers in the Syrian context, and will likely be useful for other 
developing countries in the Middle East that share similar cultural and tobacco use patterns.  
Methods 
Study design 
We analyzed data from a multi-site two-group, parallel-arm, double-blind, randomized, 
placebo-controlled trial that was conducted in four primary healthcare centers in Aleppo, Syria in 
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2008. All Eligible and interested smokers received physician-delivered face-to-face behavioral 
counseling and brief telephone support, and then randomized to receive either active transdermal 
nicotine (TN) patches or placebo TN patches. A total of 269 smokers (age 18-65 years old), who 
had smoked > 5 cigarettes/day for at least one year were recruited. Exclusion criteria were (i) a 
diagnosis of generalized dermatology disease, liver failure, hyperthyroidism or 
pheochromocytoma; (ii) current use of psychotropic drugs; (iii) past year history of drug or alcohol 
abuse; (iv) current unstable cardiovascular or psychiatric illness, or any other debilitating disease 
based on their physician’s assessment; (v) currently pregnant, lactating or intending to become 
pregnant during the next three months. Participants were patients who resided within the catchment 
area of one of the four centers included in the study. Each center had a primary care physician who 
delivered the smoking cessation intervention, served as the study coordinator, and liaised between 
the centers’ physicians and the research staff to ensure adherence to the study protocol.  The study 
was approved by the Institutional Review Boards of The University of Memphis and Syrian Center 
for Tobacco Studies. Full details of the trial design and its methods are published elsewhere (Ward 
et al., 2013). 
Procedures and intervention delivery  
Patients who were interested in quitting were referred by their primary physician to the 
cessation coordinator. Upon referral, the cessation coordinator described the study, screened 
participants for eligibility, and obtained a written informed consent from them. Patients who were 
not interested and/or ineligible were provided with self-help materials and referred back to their 
original physician. After recruitment, participants completed a battery of baseline questionnaires 
including: demographic characteristics, smoking history (e.g., number of cigarettes smoked per 
day, level of dependence, previous quit attempt, interest in quitting), self-efficacy, stage of change, 
nicotine withdrawal symptoms, and depression/mood.  Participants then were randomized using 
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random permuted blocks stratified by clinic and gender to receive either behavioral counseling + 
active TN patches (active treatment group) or behavioral counseling + placebo TN patches (control 
group). The intervention delivered during six weeks, then participants were followed at end of 
treatment (6 weeks after quit date), and at 6- and 12-months. 
Pharmacological Intervention 
Patients in the nicotine group received a six-week supply of Nicotinell™ patches, 24-hour 
dose, using a step-down algorithm. Patients who smoked ≥10 cigarettes/day received a 2-week 
supply of 21-mg patches, then a 2-week supply of 14-mg patches, then a 2-week supply of 7-mg 
patches. Patients who smoked 5–9 cigarettes per day received a 4-week supply of 14-mg patches, 
then a 2-week supply of 7-mg patches. Patients in the placebo group received the same step-down 
algorithm. Placebo patches were provided by a local manufacturer and looked identical to the 
nicotine patches (Ward et al., 2013). 
Behavioral counseling 
All patients received a culturally adapted behavioral smoking cessation intervention 
developed and tested in a pilot trial in the same population (Asfar et al., 2008; Fiore et al., 2008). 
Participants in both groups received the same intervention that includes three individual in-person 
sessions (approximately 30 min each) and five brief phone calls (approximately 10 min).  
Measures 
Baseline variables  
Predictors that were assessed at baseline include: Socio-demographic characteristics (age, 
gender, marital status, number of people in the house, years of education and religion); smoking 
history (number of years as a cigarette smoker; age when daily smoking began, current amount 
smoked per day), waterpipe use and dose of the treatment for patch (high vs. low dosage scheme).  
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Assessment of Motivation to quit was done using the Readiness to Quit Ladder (Biener and Abrams 
1991), higher score represents greater levels of readiness to quit. The scale consist of 10 items and 
provides a continuous metric of motivation and/or readiness to quit. Confidence in ability to quit 
was also assessed using a 10 items continuous metric scale. 
The Fagerström Test for Nicotine Dependence (FTND) was used for assessing the intensity of 
physical addiction to nicotine and it contains six items that evaluate the quantity of cigarette 
consumption, the compulsion to use, and dependence. (Heatherton et al., 1991).  
Time-varying variables  
The Multidimensional Scale of Perceived Social Support (MSPSS), was used to measure 
social support throughout the study. MSPSS is a brief research tool designed to measure perceptions 
of support from 3 sources: Family, Friends, and a Significant Other (Zimet et al., 1988).   
Depressive symptomatology was assessed using the Center for Epidemiologic Studies 
Depression Scale (CES-D). The 20 items in CES-D scale is a self-report instrument composed of 
20 items, and respondents are asked to rate how often they experienced symptoms (Sadness, 
Dysphoria, Loss of Interest, Appetite, Sleep, Thinking/ concentration, Guilt, Fatigued, Agitation 
and Suicidal ideation) of depression during the past week (Radloff, 1977). Participant’s belief 
whether they had received active nicotine or placebo patches was measured using this question 
[Which patch do you think you have been using? nicotine or placebo]. Adherence to treatment 
(pharmacological and behavioral counseling) was assessed throughout the entire period of 
treatment (6 weeks). 
Nicotine Withdrawal Symptoms 
Nicotine withdrawal symptoms were assessed using the Minnesota Nicotine Withdrawal 
Scale (MNWS) (Hughes and Hatsukami, 1986) and was measured at baseline, session 2 (one week 
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post-quit), session 3 (two weeks days post-quit), end of treatment (six weeks post-quit), and at the 
6- and 12-month follow-up sessions. The mean of eight scale items (depression/feeling blue, 
difficulty concentrating, hunger, increased appetite, insomnia, irritability/ frustration/anger, 
restlessness, and anxiety), was calculated to obtain a total withdrawal score (Hughes and Hatsukami 
1986, 1998) and was measured on a range of possible values of 0 (not present) to 100 (most severe) 
for the past week.  
Statistical analysis  
Descriptive statistics were used to examine participants’ demographic and smoking history 
characteristics at baseline. The generalized estimating equation (GEE) procedure was used to assess 
the longitudinal effects of baseline and time varying variables on the total nicotine withdrawal score 
throughout the entire period of the study (from baseline through 12 months follow up). A separate 
model was built to assess early withdrawal symptoms (from baseline through six weeks post quit 
day). GEE allows to estimate the parameters of the generalized linear model with a possible 
unknown correlation between outcomes, accounts for time-dependent covariates, and allows for 
specifying the random and fixed effect (Zeger et al., 1988). We used a model that considered all 
variables of interest (complete model). Social support, depression and the perception of treatment 
allocation were modeled in GEE as time varying predictors (i.e., repeated measures analysis).  All 
analyses were conducted using SPSS version 21 (SPSS Inc., Chicago, IL, USA). An alpha of 0.05 
was used to define statistical significance. 
Results 
Males comprised 78 % of the sample. The mean age of study participants was 39.9 years 
(Standard Deviation [SD] =11.4), with a mean of 10.2 years of education (SD=4.0). The mean 
number of cigarettes smoked per day was 27.7 (SD=12.7), while the mean age for starting daily 
smoking was 18.6 years (SD=5.3). The mean of Fagerström nicotine dependence score was 5.7 
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(SD=2.2), while the mean for the total withdrawal score at baseline was 28.9 (SD=18.6). The two 
treatment groups (nicotine vs. placebo) did not differ significantly on any of the baseline 
characteristics (table 1). 
Finding from the GEE linear regression, indicated that throughout the entire study period, 
lower total withdrawal score was associated with greater years of education [β=-0.008 (95%CI= -
0.016, -0.001), p=0.044], older age of smoking initiation [β=-0.006 (95%CI= -0.012, -0.001), 
p=0.017], greater adherence to patch [β=-0.090 (95%CI= -0.169,-0.011), p=0.026], smoking 
waterpipe at baseline [β=-0.080 (95%CI= -0.596,-0.001), p=0.047] and higher confidence in ability 
to quit smoking [β=-0.015 (95%CI= -0.027,-0.002), p=0.020]. On the other hand, higher total 
withdrawal score was associated with greater baseline nicotine dependence [β=0.021 (95%CI= 
0.003, 0.038), p=0.024], greater self-reported depression [β= 0.013 (95%CI= 0.011, 0.016), 
p<0.001] and the belief that one had received placebo (not nicotine) patches [β= 0.065 (95%CI= 
0.015, 0.115), p =0.011] (table 2). To assess predictors of early withdrawal severity during the 
duration of the treatment (6 weeks) we ran a secondary GEE analysis.  Similar to the primary model, 
adherence to patch use [β= -5.543 (95%CI= -9.817,-1.269), p=0.011], and greater self-reported 
depression [β=0.401 (95%CI= 0.211, 0.592), p<0.001] was associated with higher withdrawal 
severity (table 3). 
Discussion 
This is the first study to examine predictors of nicotine withdrawal severity during smoking 
cessation trial in a low-income country. Throughout the study, lower total withdrawal score was 
associated with lower baseline nicotine dependence, higher confidence in ability to quit, lower 
depression, belief that one had received nicotine patch rather that placebo, greater years of 
education, older age of smoking initiation, greater adherence to patch, and waterpipe use.  Our 
findings provide insight about factors that influence nicotine withdrawal symptomology among 
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smokers undergoing cessation trial in a low-income country setting. The results of this study offer 
an important guide on the pattern and the severity of nicotine withdrawal symptoms and deliver 
valuable information for clinicians and researchers in designing tailored and effective cessation 
interventions in low-income countries.  
Throughout the study, participants who reported higher confidence in the ability to quit at 
baseline experienced less severe nicotine withdrawal symptoms. Likely, this is because those who 
manifest higher confidence in ability to quit were more successful in maintaining abstinence and 
therefore experience less severe withdrawal. This finding emphasize the role of building confidence 
in self-ability to quit and strengthening self-efficacy prior to quit attempt to improve cessation 
outcomes (Nides et al., 1995).  
It is also noteworthy, that waterpipe smoking at baseline was associated with less severe 
withdrawal symptoms throughout the study. It’s possible that some smokers switch to waterpipe as 
substitute to cigarette during their quit attempt, which was also observed in a previous pilot 
behavioral cessation RCT from our team publication of our trial (Asfar et al., 2008). Additionally, 
qualitative evidence from the same population has shown that some cigarette smokers intentionally 
switch to waterpipe after quitting cigarettes to satisfy their craving for nicotine (Hammal et al., 
2008). This highlight the fact that waterpipe smoking can serve as a barrier to smoking cessation 
efforts in countries where its use is highly prevalent.  
On the other hand, more severe nicotine withdrawal symptoms were associated with 
younger age of smoking initiation, higher level of nicotine dependence at baseline and fewer years 
of education. However, there was no association between withdrawal severity and daily cigarette 
smoking at baseline. One might expect that heavier smokers at baseline would experience greater 
nicotine withdrawal severity throughout the study. Nevertheless, it should be noted that although 
withdrawal discomfort is related to loss of nicotine, it would not necessarily follow that it is also 
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closely associated with the amount of daily cigarette consumption at baseline. This could be 
explained by the fact that levels of nicotine intake actually depend more on how the cigarettes are 
smoked than on the quantity of cigarettes being smoked. It is well known that smokers vary 
significantly in the amount they puff and inhale from their cigarettes; therefore, the measure of 
daily cigarette consumption at best only offers a crude guide to levels of nicotine intake (West and 
Russell 1985). 
During the study, adherence to patch, regardless of whether it contained active nicotine or 
placebo, predicted less withdrawal.  Similarly, the belief that one was assigned to active nicotine 
patch, regardless of actual assignment, predicted less withdrawal symptoms.  In contrast, actual 
assignment to nicotine patch had no effect on withdrawal. Effects of expectancies appear to be 
specific to pharmacological treatment, because withdrawal severity was not predicted by adherence 
to behavioral counseling.  Thus, expectancies about medication effects, rather than actual 
pharmacologic effect, seem to be a key mechanism in nicotine withdrawal relief in this sample.  
This has also been shown in previous studies, where expectations about receiving active nicotine 
rather than placebo was associated with less withdrawal symptoms, better cessation outcomes and 
greater adherence to cessation treatment (Dar et al., 2005; Darredeau et al., 2010; Taleb et al., 
2015).  
Our results lend further support to findings by Ward and colleagues (2013) that in a “real 
life” (primary care) setting in a low-income country, unlike most results from highly controlled 
cessation trials in high-income countries, nicotine patch may not offer much benefit for reducing 
withdrawal or promoting long term abstinence. However, the role of pharmacological therapy in 
decreasing withdrawal symptoms should not be underestimated. Certainly, the results of this trial 
need to be followed up in other populations and settings, to determine whether better control of 
withdrawal symptoms is possible pharmacologically.  However, if this finding of limited utility for 
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pharmacotherapy is confirmed in other studies, it would indicate the need to culturally adapt 
behavioral strategies to control withdrawal, such as coping skill training and educating quitters 
about the time course and cognitive vs. pharmacological determinants of withdrawal symptoms.  A 
challenge to such an approach in countries such as Syria is the strong belief that medical 
consultations should result in a prescription for medication, together with the lack of 
familiarity/belief in behavioral treatment, and the belief that using medication is the most effective 
way to quit smoking (Asfar et al., 2008).   
Another important finding of this study was the positive association between depression 
and withdrawal symptoms.  This is in accordance with previous studies in high-income countries, 
which showed that depressed smokers appear to experience more severe withdrawal symptoms 
while quitting (Covey et al., 1990; Hall et al., 1992; Morrell et al., 2008), and therefore, they are 
less likely to be successful at their quitting attempts. Our results emphasize the role of depressed 
mood in predicting the intensity of the withdrawal syndrome in a low-income country setting, and 
the need to incorporate treatment for depression in smoking cessation programs (e.g., Shiffman et 
al., 2000). 
This study comes with a few limitations. This is the first prospective study of nicotine 
withdrawal symptoms in a low-income country, but results may not generalize to other countries 
and treatment settings.  Nonetheless, the similarity of many predictors of withdrawal between our 
study and others conducted in high-income countries supports the robustness and generalizability 
of our findings. Another point of consideration is that our results are based on self-reports of 
withdrawal symptoms; however, we employed a widely- accepted and reliable instrument for the 
assessment of nicotine withdrawal symptoms (Shiffman et al., 2004). Lastly, we did not collect 
information regarding passive smoking exposure at home or at work place. Therefore, we were not 
able to assess how it may influenced the severity of nicotine withdrawal symptoms in our study.  
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Conclusions 
In summary, our study shows that in a real world setting in a low-income country, the 
expectancy of an effect from patch, rather than the pharmacological effect of nicotine replacement 
per se, mediates the effect on withdrawal symptoms severity. Furthermore, greater confidence in 
ability to quit and waterpipe use at baseline were associated with less severe withdrawal symptoms. 
Additionally, similar to findings from high-income countries, more severe withdrawal symptoms 
were associated with higher nicotine dependence, younger age of initiation, lower education and 
greater self-reported depression. This knowledge will help in advancing the treatment of smoking 
dependence by informing intervention schemes so it targets important sources of withdrawal 
phenomena, and those likely to experience more withdrawal in low-income countries. Our findings 
deliver a guide on the pattern and the severity of nicotine withdrawal symptoms and provide 
valuable information for clinicians and researchers in designing tailored and effective cessation 
interventions in low-income countries.  
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Tables and figures 
Table.1 Baseline characteristics by treatment condition among cessation trial participants (Syria 
2008)  
Variables* Overall sample Placebo Nicotine 
Age  39.9 (11.4) 40.0 (11.4) 39.9 (11.4) 
Gender (male %) 78.4 81.5 75.4 
Education(years completed) 10.3(4) 10.4 (4.1) 10.2 (4.0) 
Number of people in the house  5.3 (2.7) 5.3 (2.5) 5.4 (2.6) 
Marital status (Married %) 79.2 81.5 76.9 
Religion (Muslim %) 74.7 74.8 74.6 
Amount smoked (cigarettes/day) 27.7(12.7) 27.4 (11.5) 28.1 (13.9) 
Age when smoked at least one cigarette per day 18.7(5.3) 18.6 (5.0)  18.7 (5.6) 
Readiness to quit scorea 7.8(0.9) 9.1 (1.3) 8.9 (1.3) 
Fagerstrom Test of Nicotine Dependenceb 5.7(2.2) 5.6 (2.1) 5.9 (2.3) 
Confidence in ability to quitc  6.9(2.4) 7.0 (2.3) 6.9 (2.5) 
Social supportd 43.1 (10.2) 44.8 (8.9) 41.0 (11.2) 
Nicotine withdrawal symptomse score 28.9(18.9) 28.4 (17.9) 29.5 (19.4) 
Depressions (CES-D) scoref 18.0(10.1) 17.2 (10.0) 18.9 (10.2) 
Water pipe use (%) 10.8 11.1 10.4 
Carbon monoxide (p.p.m.) 27.5(15.2) 27.6 (15.7) 27.4 (16.6) 
*For continuous variables, a two-sample t test evaluated differences in means. For dichotomous variables, a chi-square test evaluated 
differences in proportions. aRange of possible values for readiness to quit is 0–10. bRange of possible values for the Fagerstrom Test of 
Nicotine Dependence is 0–10. CRange of possible values for confidence in ability to quit is 0–10. dRange of possible values for the social 
support score is 0–60. eRange of possible values of possible values for the total withdrawal score is 0-100. fRange of possible values for 
CES-D score is 0–60 
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Table.2 Predictors of withdrawal symptoms from baseline to 12-month follow-up among 
cessation trial participants determined by generalized estimating equation (GEE) linear regression 
(Syria 2008) 
Variables  β 95% CI P-value¶ 
Age -0.010 -0.023, 0.002 
 
0.078 
Gender  
Male 
Female 
 
0.070 
      Ref 
 
-0.003, 0.142 
 
 
0.060 
Education years  -0.008 -0.016, -0.001 
 
0.044 
Treatment  
Nicotine 
Placebo 
 
-0.001 
Ref 
 
-0.064, 0.062 
 
0.981 
Dose of treatment (patch) 
High 
Low 
 
-0.020 
Ref 
 
-0.164, 0.124 
 
0.785 
Age when began smoking one cigarette per day -0.006 -0.012, -0.001 
 
0.017 
Total years of smoking at least one cigarette per day -0.003 -0.006, 0.001 
 
0.114 
Amount smoked (Cigarettes/day) -0.003 -0.007, 0.001 0.197 
Waterpipe use  
Smoker 
Non-smoker 
 
-0.080 
Ref 
 
-0.596, -0.001 
 
0.047 
Fagerstrom Test of Nicotine Dependence 0.021 0.003, 0.038 0.024 
Motivation to quit (how motivated are you to quit) -0.009 -0.032, 0.014 0.438 
Confidence to quit (How confident are you that you can quit) -0.015 -0.027, -0.002 0.020 
Adherence to patch 
Adherent  
Non-Adherent  
 
-0.090 
Ref 
 
-0.169, -0.011 
 
0.026 
Adherence to behavioral counseling  
Adherent 
Non-adherent  
 
0.010 
Ref 
 
-0.081, 0.101 
 
0.827 
Depression score* 0.013 0.011, 0.016 <0.001 
Social support*  0.001 -0.001, 0.004 0.342 
Perception of treatment allocation* 
Placebo 
Nicotine  
 
0.065 
Ref 
 
0.015, 0.115 
 
0.011 
¶ p-value<0.05 indicated in bold.  * modeled as repeated measures.  
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Table 3. Predictors of withdrawal symptoms from baseline to end of treatment (6 weeks post quit 
day) among cessation trial participants determined by generalized estimating equation (GEE) 
linear regression (Syria 2008) 
¶ p-value<0.05 indicated in bold.  * modeled as repeated measures.  
 
 
 
 
Variables  β 95% CI P-value¶ 
Age -0.402 -0.895, 0.091 
 
0.110 
Gender  
Male 
Female 
 
2.078 
      Ref 
 
 -3.016, 7.172 
 
 
0.424 
Education years  0.083 -0.296, 0.462 
 
0.668 
Treatment  
Nicotine 
Placebo 
 
1.568 
Ref 
 
-1.792, 4.927 
 
0.360 
Dose of treatment (patch) 
High 
Low 
 
0.802 
Ref 
 
-5.473, 7.078 
 
0.802 
Age when began smoking one cigarette per day 0.405 -0.080, 0.890 
 
0.120 
Total years of smoking at least one cigarette per day 0.157 -0.396, 0.710 
 
0.578 
Amount smoked (Cigarettes/day) -0.092 -0.328, 0.143 0.442 
Waterpipe use  
Smoker 
Non-smoker 
 
-2.416 
Ref 
 
-7.707, 2.874 
 
0.371 
Fagerstrom Test of Nicotine Dependence 0.273 -0.666, 1.213 0.568 
Motivation to quit (how motivated are you to quit) -0.321 -0.168, 1.046 0.645 
Confidence to quit (How confident are you that you can quit) -0.688 -1.436, 0.060 0.071 
Adherence to patch 
Adherent  
Non-Adherent  
 
-5.543 
Ref 
 
-9817, -1.269 
 
0.011 
Adherence to behavioral counseling 
Adherent 
Non-adherent  
 
-4.286 
Ref 
 
-10.37, 1.803 
 
0.168 
Depression score* 0.401 0.211, 0.592 <0.001 
Social support*  0.074 -0.071, 0.218 0.316 
Perception of treatment allocation* 
Placebo 
Nicotine  
 
1.006 
Ref 
 
-2.484, 4.495 
 
0.572 
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MANUSCRIPT 3 
Smoking cessation and changes in Body Mass Index: findings from the first randomized 
cessation trial in low-income country setting 
Abstract 
Background: In high-income countries, quitting cigarette smoking is associated with weight gain, 
which can reduce motivation to abstain. Whether smoking cessation is associated with weight gain 
in a low-income country context has never been investigated. Aim: to determine the post-cessation 
changes in body mass index (BMI) and its predictors among smokers who received a smoking 
cessation intervention in a low-income country setting. Methods: We performed an ancillary 
analysis of data from 269 smokers who participated in a multi-site, two-group, parallel-arm, 
double-blind, randomized, placebo-controlled smoking cessation trial in primary care clinics in 
Aleppo, Syria. We used generalized estimating equation (GEE) modeling to identify predictors of 
changes in BMI at 6 weeks, 6- and 12-month follow-ups after quit date.  Results: The mean pre-
cessation BMI of the sample was 27.9 kg/m2 (SD= 5.2). Smoking abstainers had 1.8 BMI units 
(approximately 4.8kg) greater than non-abstainers over one year post quitting (P=0.012). 
Throughout the study, higher BMI was associated with being female (P=0.048), reporting smoking 
to control weight (P<0.001) and having previously failed to quit due to weight gain (P=0.036). 
Conclusion: Similar to findings from high-income countries, smoking cessation in Syria is 
associated with weight gain, particularly among women and those who have weight concerns prior 
to quitting. This group of smokers may benefit from tailored cessation interventions with integrated 
body weight management elements that take into consideration the prevailing local and cultural 
influences on diet and levels of physical activity. 
KEYWORDS: weight gain, post-cessation, smoking, BMI, developing countries 
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Introduction 
While quitting smoking improves health, several barriers may impede willingness to quit 
and ability to maintain abstinence. One of the most cited causes of failure to quit smoking is the 
fear of post-cessation weight gain (Jeffery et al., 2000; Perkins, 1993).  Concerns related to weight 
gain following smoking cessation may discourage smokers from making a quit attempt (Pomerleau 
et al., 2001), and post-cessation weight gain may trigger relapse (Pisinger & Jorgensen, 2007).  
The relationship between smoking cessation and weight gain is well established (Ward et 
al., 2001). On average, smokers tend to weigh less than never smokers, and former smokers weigh 
more than current smokers (Flegal et al., 1995; Travier et al., 2009). Findings from prospective 
studies indicate that smoking cessation produces an average weight gain of 4–5 kg (Aubin et al., 
2012; Eisenberg & Quinn, 2006; Klesges et al., 1997, 1998; Lycett et al., 2011; Williamson et al., 
1991) and a body mass index (BMI) increase of around 1.6 kg/m2 after one year of abstinence 
(Munafò et al 2009; Owen-Smith & Hannaford, 1999).  
Evidence from high-income countries has documented several factors associated with post-
cessation weight gain. These include younger age (Wane et al., 2010), female gender (Williamson 
et al 1991), low socioeconomic status (Swan and Carmelli, 1995), lower baseline weight, nicotine 
dependence, and sedentary lifestyle (Hall et al., 1986). Moreover, using nicotine replacement 
therapy (NRT) reduces weight gain during the treatment; however, this effect is not maintained 
during long-term abstinence (Farley et al., 2012).  
Prevalence and predictors of post-cessation weight gain may be different in low income 
compared to high income countries, since many risk factors differ.  For example, Syrian smokers 
tend to be heavy smokers and nicotine dependent, and many also smoke waterpipes, factors which 
are usually associated with increased weight and obesity (Williamson et al., 1991; Shafique et al., 
2012; Ward et al., 2014). On the other hand, people living in low-income countries may be less 
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concerned about weight gain and have different rates of obesity than those living in high-income 
countries probably due to differences in socioeconomic status, and cultural and life style factors 
such as level of physical activity and diet choices (Badran and Laher, 2011; Fouad et al., 2006). To 
the best of our knowledge, no previous study evaluated weight gain by smokers treated with a 
combination of pharmacological and behavioral cessation treatment in low-income countries.  The 
main objective of the present study is to determine predictors of post-cessation changes in BMI 
among smokers who participated in a smoking cessation intervention in a low-income country 
setting (Ward et al., 2013). 
Methods 
Study design 
This study utilized data from a multi-site, two-group, parallel-arm, double-blind, 
randomized, placebo-controlled trial conducted in primary care clinics in Aleppo, Syria in 2008. 
Smokers who were interested and eligible to participate in the study were randomized to receive 
either behavioral cessation counseling + active transdermal nicotine patches (TN), or behavioral 
cessation counseling + placebo TN. A total of 269 smokers (18–65 years old) who had smoked at 
least 5 cigarettes/day for at least one year were recruited. Exclusion criteria included (1) a diagnosis 
of generalized dermatology disease, liver failure, hyperthyroidism or pheochromocytoma; (2) 
current use of psychotropic drugs; (3) past year history of drug or alcohol abuse; (4) current unstable 
cardiovascular or psychiatric illness, or any other debilitating disease based on their physician’s 
assessment; (5) currently pregnant, lactating or intending to become pregnant during the next three 
months. Participants were patients who lived in Aleppo, and were registered at one of the four 
primary care clinics that were included in the study.  These clinic provided cost free health care, 
and most of the patents attending these clinics have low socioeconomic status. Each clinic had a 
primary care physician who functioned as a cessation coordinator.  The cessation coordinator 
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liaised between other physicians and clinic-staff to ensure adherence to the study protocol, and 
delivered the intervention to the participants. Full details of the trial and its methods are published 
elsewhere (Ward et al., 2013). 
Procedures 
At the baseline assessment, participants provided demographic data, smoking related 
information (e.g., smoking history, level of dependence, waterpipe use, number of cigarettes 
smoked per day) and concerns regarding weight gain. Participants were then assigned to one of two 
treatment conditions [Arm A (n = 134): behavioral counseling + active TN vs. Arm B (n = 135): 
behavioral counseling + placebo TN] using random permuted blocks, stratified by clinic and 
gender. After quit date, participants received 3 follow-up assessments and completed additional 
questionnaires to assess adherence to cessation treatment, withdrawal symptoms, 
and depression/mood.  
Patients in the active treatment group received a six-week supply of Nicotinell™ patches, 
24-h dose, using a step-down algorithm. Patients in the placebo group received the same step-down 
algorithm. Placebo patches were provided by a local manufacturer (Asfar et al., 2016). 
Additionally, all patients received physician-delivered face-to-face behavioral counseling and brief 
telephone support, using approaches shown to be effective in developed countries (Fiore et al., 
2008) and adapted for the local Syrian culture based on pilot work (Asfar et al., 2008). Three 
individual, in-person sessions (approximately 30-min each) and 5 brief (approximately 10-min) 
phone calls, were delivered by the cessation interventionists. 
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Measures 
Baseline variables 
Socio-demographic characteristics (age, gender, density index, years of education); 
smoking-related variables (number of years as a cigarette smoker; onset of daily smoking, number 
of cigarettes smoked per day, waterpipe use). Weight concern at baseline was assessed using a 
variable reflecting smoking to control weight “I smoke to control weight” adapted from the 
Smoking Situations Questionnaire (Weekly et al., 1992), which was recoded as binary. [0=No, 
1=Yes]. Previous failed attempts to quit due to weight gain was assessed by responding [0=No, 
1=Yes] to the statement “I have been unsuccessful in my past attempts to quit because of weight 
gain”. The Fagerström Test for Nicotine Dependence (FTND) was used for assessing the intensity 
of physical addiction to nicotine (Heatherton et al. 1991). 
Time varying variables  
The following factors were assessed at end of treatment (6 weeks post quit), 6- and 12- 
months follow ups: Depressive symptomatology was assessed using the Center for Epidemiologic 
Studies Depression Scale (Radloff 1977), while abstinence from smoking (7 day point-prevalence 
abstinence defined as self-report of not smoking in the past 7 days and verified by exhaled carbon 
monoxide levels of <10 ppm). Overall adherence to treatment (nicotine patch and behavioral 
counseling) was assessed throughout the entire period of treatment (every week for 6 weeks) (Taleb 
et al., 2015).  
Study outcome 
The main outcome was body mass index (BMI). Weight was measured to the nearest 0.1 
kg using a digital scale equipped with a high-precision strain gauge sensor, and height was 
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measured to the nearest cm using a portable stadiometer. We divided the body weight (in kg) by 
the body height (in m2) to calculate the BMI (Ward et al., 2014). 
Statistical analysis 
Descriptive statistics for the baseline characteristics of the study sample were summarized 
with means and standard deviations (SD) or proportions. Means and SDs for weight, BMI, waist 
circumference and changes in weight and BMI were summarized and compared across abstinence 
status at 6 weeks, and 6- and 12-month follow-ups. Differences in continuous variables were 
analyzed with the two- sample t- test, or with the Mann- Whitney test as appropriate.  All variables 
of interest were checked for collinearity using the variance inflation factor (VIF). The generalized 
estimating equation (GEE) procedure was used to assess the longitudinal effects of baseline and 
time varying variables on BMI measurements throughout the entire period of the study. GEE allows 
estimation of the parameters of generalized linear model with a possible unknown correlation, 
accounts for time-dependent covariates, and allows for specifying random and fixed effects (Zeger 
et al. 1988). Model building followed the methods described by (Reed and Kass, 2010; Hardin & 
Hilbe, 2003), and the goodness of fit was assessed using the quasi likelihood under independence 
model criterion (QIC) (Hardin & Hilbe, 2003). The analyses were adjusted by age and gender and 
were conducted using SPSS version 21 (SPSS Inc., Chicago, IL, USA). An alpha of 0.05 was used 
to define statistical significance. 
Results 
Among the 269 participants at baseline, males comprised 78 % of the sample. The mean 
age of study participants was 39.9 years (Standard Deviation [SD] =11.4), with a mean of 10.2 
years of education (SD=4.0). The mean number of cigarettes smoked per day was 27.7 (SD=12.7), 
while the mean age for starting daily smoking was 18.6 years (SD=5.3) and the mean Fagerström 
nicotine dependence score was 5.7 (SD=2.2). Mean weight was 80.3 Kg (SD=16.2), mean BMI 
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was 27.9 Kg/m2 (SD=5.2) and mean waist circumference was 95.7 (SD=12.5). Other baseline 
characteristics of the sample are summarized in table 1. 
Table 2 presents mean values of weight, waist circumference, BMI and changes in weight 
and BMI at different time points of the study by abstinence status. Compared with non-abstainers, 
smoking abstainers gained significantly more weight at 6 weeks, 6- and 12-month follow-ups, and 
had greater BMI and greater waist circumference at the 6- and 12-month follow ups. 
Findings from the GEE linear regression model (Table 3) indicated that throughout the entire study 
period, higher BMI was associated with: being abstinent from smoking [β= 1.869 (95%CI= 0.405, 
3.333) p=0.012], having weight concerns at baseline (smoking to control weight) [β= 2.587 
(95%CI= 1.314,3.859) p<0.001], being female [β= 2.172 (95%CI= 0.023,4.321) p=0.048], and 
attributing past failed quit attempts to weight gain [β= 2.461 (95%CI= 0.159 , 4.762) p=0.036]. 
 Being assigned to active nicotine treatment and adherence to cessation treatment were not 
significantly associated with BMI, nor was there a significant interaction between treatment 
condition and adherence to treatment. Furthermore, gender × abstinence status, gender × weight 
concerns and waterpipe smoking × abstinence status interactions terms were also not significant in 
the multivariable model (all p-values>0.05). 
Discussion 
This is the first study to examine BMI change and its predictors among smokers who 
attempted to quit smoking in a low-income country setting.  Smoking abstainers experienced an 
average weight increase of 4.8 kg over a one year follow-up. Throughout the study, higher BMI 
was associated with abstinence from smoking, reporting smoking to control weight at baseline, 
failure to quit in the past due to weight gain, and being female. This information provide insight 
about factors that influence weight changes among smokers attempting to quit in a low-income 
  
 
55 
 
country setting and will help in identifying smokers who are at higher risk of gaining weight post-
cessation. 
Consistent with findings from high-income countries, our study shows that participants 
who maintained abstinence from smoking experienced an increase of 1.8Kg/m2 more than non-
abstainers. For an adult of average height in Syria (161.4 cm; Fouad et al., 2006) this BMI 
difference translates to 4.8kg (10.5 lbs.) of body weight.  Our findings are in line with other studies 
reporting that most quitters gain about 4–5 kg in the first year (Aubin et al., 2012) and around 1.6 
kg/m2 over the same time frame (Munafò et al., 2009; Owen-Smith & Hannaford, 1999).   
Several factors have been suggested to explain the post-cessation weight gain. These 
include an increase in caloric intake, a decrease in body metabolic rate (Filozof et al., 2004; Perkins, 
1993) or a reduction in the role of physical activity (Perkins et al., 1989; Grunberg and Bowen, 
1985). The weight reduction effect of nicotine usually occurs due to acute increases in resting 
metabolic rate along with an anorectic effect that reduces food intake (Ward et al., 2001). Therefore, 
when smokers quit, the loss of the metabolic enhancement and appetite suppression effect of 
nicotine lead to an increase in caloric intake that usually is not offset by increased physical activity. 
This positive energy imbalance consequently leads to weight gain (Audrain‐McGovern and 
Benowitz 2011). In addition, our data shows that the most severe nicotine withdrawal symptoms 
experienced by abstainers were increased eating and hunger, which further contributes to increased 
caloric intake and weight gain (data not shown).   
A systemic review that was done in 2012 to evaluate the effect of pharmacological 
treatment on post-cessation weight changes showed that NRT might prevent or at least attenuate 
weight gain (Farley et al., 2012). However, other investigations could not confirm this finding 
(Prod’hom et al., 2013; Allen et al., 2013). Similarly in our study, we found no association between 
being on active NRT (vs placebo) and changes in BMI post-quitting. In addition, we found no 
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association between adherence to cessation treatment and changes in BMI.  However, we did not 
provide other forms of pharmacological treatment such as varenicline, which based on recent 
evidence (Taniguchi et al., 2014) might be more effective in lessening post-cessation weight gain 
than NRT. 
Similar to previous findings (Pisinger and Jorgensen, 2007), throughout the period of our 
study, women had higher BMI than men.  The mechanism in which women gain more weight after 
quitting smoking is not yet well understood. However, it was previously shown that women are 
more concerned about their weight than men, and therefore, they may use smoking to 
suppress appetite or as a substitute to eating to stay in shape (French et al., 1994; Meyers et al., 
1997). Further, numerous studies have shown that women experience higher energy intake post-
cessation than men leading to a greater weight gain (Levine et al., 2012; Ward et al., 2001; Nides 
et al., 1994; Klesges et al., 1990). In addition, women who live in low-income countries may have 
less active life style due to social restrictions. For example, in Syria, women are more often 
confined to their homes, either due to societal traditions or their pressing household duties and have 
probably less time and access to recreational and physical activities (Maziak, 2009). 
Our results show that participants who reported failing in previous quit attempts due to 
weight gain or utilizing smoking as a way to control weight at baseline had higher BMI than those 
who did not. This is consistent with previous studies from high-income countries (Meyers et al., 
1997; Pomerleau et al. 1993; Weekley et al. 1992). Evidence suggests that weight-control smokers 
have low efficacy in managing their food intake especially while dealing with negative emotions 
(Pinto et al., 1999). Using a combination of exercise, relaxation techniques and diet may help those 
smokers avoid overeating. It is also important that adjunct weight-control treatment or cognitive 
restructuring therapy regarding beliefs about weight control are incorporated into cessation 
programs to improve cessation rates. In fact, cognitive behavioral treatment designed to address 
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weight concerns has been reported to increase rates of cessation and attenuate weight gain when 
compared with standard cessation programs (Perkins et al., 2001).  
The present study has some limitations. The relationship between smoking cessation and 
weight gain is complex and multifactorial. There is likely a constellation of characteristics that is 
related to post-cessation weight gain such as higher levels of dietary intake and exercise behavior 
which we did not evaluate in our trial.  Nevertheless, our results are in line with previous research 
from high-income countries, which further support the robustness of our findings, and point at some 
universal mechanisms governing weight gain in smoking cessation. 
Conclusions 
In summary, this is the first study to investigate post-cessation weight gain in a low-income 
country health care setting. A main result of our investigation is that similar to findings from high-
income countries, smokers gain weight when they quit smoking, averaging 4.8 Kg (10.5 lbs) over 
one year.  Additionally, women, and those who reported smoking to control weight and having 
previously failed at quitting due to weight gain, were at increased risk for post-cessation weight 
gain.  This information will provide insight for clinicians and researchers involved in program 
design and cessation efforts and will help in identifying those smokers who are at higher risk of 
weight gain after quitting.   For these smokers, incorporating interventions that take into 
consideration the prevailing local and cultural influences on diet and levels of physical activity is 
recommended. Further research on the proportion of weight control smokers and how gender roles 
affect post-cessation weight gain in low-income countries is needed. 
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Tables and figures 
Table.1 Baseline characteristics for the overall sample by treatment condition (n=269).  
acalculated by dividing the number of people living in the house by the number of the rooms in the house. bRange of possible values 
for the Fagerstrom Test of Nicotine Dependence is 0–10. cRange of possible values for total withdrawal discomfort score is 0–100. 
dRange of possible values for CES-D score is 0–60.  
 
Variables Overall sample  
age  39.9 (11.4)  
Gender (male %) 78.4  
Education (Years completed)  10.2 (4)  
Density Indexa  1.5(0.9)  
Amount smoked (cigarettes/day) 27.7(12.7)  
Age when smoked at least one cigarette per day 18.7(5.3)  
Total years of smoking at least one cigarette per day 21.3(11)  
Fagerstrom Test of Nicotine Dependenceb 5.7(2.2)  
Nicotine withdrawal symptoms scorec 28.9(18.9)  
Depressions (CES-D) scored 18.0(10.1)  
Waterpipe use (%) 10.8  
Carbon monoxide (p.p.m.) 27.5(15.2)  
Weight (Kg) 80.3(16.2)  
BMI (kg/m2) 27.9(5.2)  
Waist circumference (cm)  95.7(12.5)  
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Table.2 Mean weight, BMI, waist circumference, and change in weight by smoking status throughout the study 
 
  Note. BMI = body mass index; Values are means with standard deviations in parentheses. *p-value<0.05 indicated in bold. 
 
 
 
 
 
 
 
 End of treatment 
(6 weeks) 
 6 months  12 months  
 Abstinent 
(n=69) 
 
Non-
abstinent 
(n=200) 
p-
value* 
Abstinent 
(n=45) 
Non-
abstinent 
(n=224) 
p-
value* 
Abstinent 
(n=47) 
Non-
abstinent 
(n=222) 
p-
value* 
Weight (kg)  
 
83.3(12.1) 82.2(13.6) 0.603 86.9(14.4) 81.7(15.2) 0.056 88.4(14.1) 79.6(15.2) 0.001 
Waist circum(cm) 100.3(10.3) 100.4(10.4) 0.965 104.6(11.7) 98.8(12.7) 0.015 105.5(13.2) 97.1(12.2) <0.001 
BMI(kg/m2) 29.4(5.3) 28.3(4.5) 0.182 30.6(5.8) 28.1(4.8) 0.007 31.3(5.5) 27.5(4.7) <0.001 
Changes in BMI 
(kg/m2) from baseline 
+0.90(1.2)  +0.53(1.1) 0.065 +1.4(1.6) -0.16(1.9) <0.001 +1.4(1.8) +0.28(1.6) <0.001 
Changes in weight  
(kg) from baseline 
+2.4(2.5) +1.4(2.9) 0.035 +4.0(4.3) -0.2(3.8) <0.001 +4.1(5.2) +0.8(3.4) <0.001 
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Table.3 Predictors of BMI changes from baseline to 12-month follow-up determined by 
generalized estimating equation (GEE) linear regression. 
¶ p-value<0.05 indicated in bold.   
 
 
Variables β 95% CI P-value¶ 
Gender  
   Female 
   Male 
 
2.172 
Ref 
  
0.023,4.321 
 
0.048 
Age 0.004 -0.220,0.228 0.971 
Years of education 0.189 -0.063,0.442 0.141 
Density Index 0.065 -0.667,0.797 0.861 
Treatment  
    Nicotine 
    Placebo 
 
0.229 
Ref 
 
-1.127,1.585 
 
0.741 
Amount smoked (Cigarettes/day) 0.042 -0.030,0.114 0.256 
Fagerstrom Test of Nicotine Dependence -0.207 -0.618,0.204 0.324 
Age when began smoking one cigarette per day 0.039 -0.190,0.269 0.737 
Total years of smoking at least one cigarette per day 0.028 -0.255,0.311 0.845 
Smoking to control weight  
    Yes 
    No 
 
2.587 
Ref 
 
1.314,3.859 
 
<0.001 
Waterpipe use  
    Smoker 
    Non-smoker 
 
-0.112 
Ref 
 
-2.878, 2.654 
 
0.937 
Adherence to patch 
   Adherent  
   Non-Adherent  
 
-0.398 
Ref 
 
-2.641,1.846 
 
0.728 
Adherence to behavioral counseling  
   Adherent 
   Non-adherent  
 
-0.788 
Ref 
 
-2.927,1.352 
 
0.471 
Depression score -0.014 -0.074,0.047 0.660 
Abstinence status 
   Abstinence 
   Non Abstinence 
 
 1.869  
   Ref 
 
0.405,3.333 
 
0.012 
unsuccessful past quit attempts quit due to weight gain 
Yes 
No 
 
2.461  
   Ref 
 
0.159 , 4.762 
 
0.036 
Total withdrawal score -0.022             -0.060,0.016 0.265 
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CONCLUSIONS 
This work provides the first comprehensive information regarding adherence to 
cessation treatment, nicotine withdrawal symptoms and post-cession weight gain among 
smokers who attempt to quit in a low-income developing country setting. 
Our study suggests that adherence to cessation treatment for cigarette smokers in 
low-income countries such as Syria may benefit from integrated cessation components that 
provide intensive treatment for subjects with higher nicotine dependence, and address 
concurrent waterpipe use at all stages. Such novel insights on factors that influence 
adherence to cessation treatment in a developing country’s setting, can help to improve 
cessation treatments for smokers living in countries at similar level of development.  
In addition, this research shows that in a real world setting in a low-income country, 
the expectancy of an effect from patch, rather than the pharmacological effect of nicotine 
replacement per se, mediates the effect on withdrawal symptoms severity. Additionally, 
more severe withdrawal symptoms were associated with younger age of initiation, lower 
education and greater reported depression. Similar to adherence to cessation treatment, 
nicotine dependence and waterpipe use were also associated with severity of nicotine 
withdrawal symptoms. It’s important that in countries like Syria where waterpipe use is 
prevalent to include a special component in cessation programs that takes into account the 
use of waterpipe concurrently with cigarettes to ensure that smokers who intend to quit will 
not substitute with waterpipe use.  
Furthermore, this research shows that abstinence from smoking was associated with 
weight gain among smokers who attempt to quit in a low-income country setting. 
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Additionally, smoking to control weight, having unsuccessful quitting attempts in the past 
due to weight gain, and being female were associated with post-cessation weight gain. This 
information has the potential to improve cessation rates by identifying smokers who are at 
higher risk of weight gain after quitting. For this group of smokers, incorporating 
interventions such as dietary regimens and physical activity into cessation programs is 
recommended. 
Collectively, our findings increase the understanding of factors that are associated 
with adherence to cessation treatment, nicotine withdrawal symptoms and post-cessation 
weight gain among smokers who attempt to quit in a low-income country setting. This 
information will provide valuable guide for clinicians and researchers in designing future 
tailored and effective cessation interventions in Syria and other countries with similar 
developmental level and cultural background.    
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